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1. Introduction
Insulin has classically been considered a hormone that acts primarily on skeletal muscle,
adipose tissue and the liver in the control of glucose homeostasis. However, recent evidence
indicates that insulin is also a vascular hormone that has an essential role in both regulating
glucose homeostasis through influencing blood flow (e.g. glucose uptake in skeletal muscle
and adipose tissue) and in maintaining vascular health.
Among the most important cardiovascular actions of insulin is to stimulate production of the
potent vasodilator nitric oxide (NO) from vascular endothelium, increasing blood flow to
skeletal muscle and other target tissues. These actions take place not only on conduit arteries
(i.e. macrovasculature), but also on resistance and terminal arterioles (i.e. microvasculature).
Abnormally high insulin concentrations (i.e. early stage of type 2 diabetes) and/or insulin
resistance (i.e. tissues do not respond to insulin normally) have a profound impact on vascular
homeostasis that manifests as impaired endothelial function, vasodilation, microvessel disease
(i.e. retinopathy and nephropathy), and enhanced vascular inflammation and atherosclerotic
lesion formation.
Approximately 90-95% of patients with diabetes mellitus have type 2 diabetes, which is
characterized by insulin resistance or the inability of insulin to exert its metabolic actions.
Indeed, early in the disease the pancreas produces more and more insulin to compensate for
insulin resistance in target tissues. Eventually the pancreas may ‘wear out’ and the patient may
no longer be able to produce insulin. Furthermore, there is good support for the notion that
insulin resistance is itself an important risk factor for cardiovascular disease.
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Thus, this chapter is intended to summarize the current available literature describing the
physiologic and pathophysiologic role of insulin in the vasculature, and the mechanisms
underlying the development of vascular insulin resistance from three standpoints. First, the
role of insulin in the vasculature will be discussed with a specific focus on the interactions
between the vascular and metabolic effects of insulin. Second, the role that vascular insulin
resistance may play in the pathogenesis of vascular disease will be explored. Finally, this
chapter will present evidence for the beneficial effects of exercise and physical activity in
managing insulin resistance (i.e. improved insulin sensitivity) and improving endothelial
function.
2. Physiological role of insulin in the vasculature
2.1. Signaling pathways
It has been more than 90 years since the role of insulin in glucose homeostasis was first
discovered. Since that time, it has been established that insulin receptors are expressed on
nearly every cell surface in the body, and great strides have been made in understanding
insulin signal transduction pathways. In the endothelium, insulin simultaneously stimulates
the production of the vasodilator NO and the vasoconstrictor endothelin-1 (ET-1) through
signaling pathways that closely parallel the insulin signaling pathways which regulate glucose
uptake and cell growth and differentiation in skeletal muscle, adipose, and other tissues.
Typically, the net result of insulin stimulation in the vasculature is vasodilation, which serves
to distribute blood flow to target tissues for glucose uptake. The hemodynamic effects of
insulin typically account for up to 40% of insulin-stimulated skeletal muscle glucose uptake
[1-10]. However, in insulin resistant states, the balance between the production of vasodilator
and vasoconstrictor substances shifts, impairing insulin-stimulated vasodilation and contri‐
buting to reductions in insulin-stimulated glucose uptake [1, 2, 11-14].
2.1.1. Insulin signaling in the endothelium — Vasodilation
The insulin receptor is a cell-surface heterotetrameric protein comprised of two extracellular
α subunits and two transmembrane β subunits joined by disulfide bonds. The binding of
insulin to the extracellular α subunits initiates conformational changes that activate intrinsic
tyrosine kinase activity on the intracellular portion of the transmembrane β subunits. Activa‐
tion of the receptor tyrosine kinase promotes trans-autophosphorylation of the β subunits as
well as the tyrosine phosphorylation of multiple docking proteins, including insulin receptor
substrates 1 (IRS-1) and 2 (IRS-2). IRS-1 is necessary for insulin-stimulated production of NO
in the endothelium [15], whereas IRS-2 is primarily implicated in delivery of insulin to the
skeletal muscle interstitium [16] but may also contribute to NO production [17].
The src homology 2 (SH2) domain of the p85 regulatory subunit of phosphoinosiditde 3-kinase
(PI-3K) binds to the tyrosine phosphorylated IRS-1, activating catalytic p110 subunit of PI-3K.
PI-3K then converts the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2)
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to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits 3-phosphoinositide-depend‐
ent protein kinase-1 (PDK1) and protein kinase B (PKB) to the plasma membrane where PDK1
activates PKB, also known as Akt. Finally, Akt directly phosphorylates endothelial nitric oxide
synthase (eNOS) at Ser1177, catalyzing the conversion of L-arginine to L-citrulline and NO.
Insulin may also stimulate the production of the vasodilator prostacyclin (PGI2) from the
vascular endothelium [18, 19]. Although the signaling mechanism appears to be independent
of insulin-stimulated NO production, it has yet to be elucidated.
2.1.2. Insulin signaling in the endothelium — Vasoconstriction
In addition to stimulating the production of NO through the PI-3K/Akt pathway, insulin also
stimulates the production of the potent vasoconstrictor ET-1 through a separate mitogen-
activated protein kinase (MAPK) pathway [20-22]. The divergence of the two pathways
originates at IRS-1 where the binding of PI3-K differentiates the NO pathway and the binding
of growth factor receptor bound protein 2 (Grb2) initiates the ET-1 pathway.
As described above, the binding of insulin to the insulin receptor initiates a cascade of
autophosphorylation events including the activation of the docking proteins IRS-1 and IRS-2.
Concurrently, the Src homology containing (Shc) protein is also activated by the insulin
receptor. Binding of the SH2 domain of Grb2 to the phosphorylated tyrosine residues of IRS-1
or Shc activates the preassociated guanosine triphosphate (GTP) exchange factor Sos (son of
sevenless). Sos activates Ras (rat sarcoma), a small GTP binding protein, that subsequently
binds and activates the serine-threonine protein kinase Raf (rapidly growing fibrosarcoma).
Raf activates MAPK/extra-cellular signal-regulated kinase (MEK) which then activates
ERK1/2, also known as p44/42 mitogen-activated protein kinase (MAPK). Activation of MAPK
ultimately leads to insulin-stimulated production of ET-1 [20]. However, the specific cell
signaling events linking the activation of MAPK and ET-1 production are poorly understood.
2.1.3. Insulin signaling in the endothelium — Opposing pahways
The branches of the insulin signaling pathway yielding NO and ET-1 are widely viewed as
distinct. However, inhibition of the MAPK pathway augments activation of eNOS, and,
conversely, blockade of the PI3K pathway enhances expression of vascular adhesion molecules
downstream of MAPK [23], indicating that there is likely some interaction between the two
branches of the insulin signaling cascade.
2.1.4. Anti-inflammatory and atheroprotective effects of insulin
The primary atheroprotective effects of insulin are exerted through the production of NO. In
addition to being a vasodilator, NO also exhibits antithrombic, antifibrinolytic, and antia‐
therogenic properties, including mitigation of cell growth and proliferation and inhibition of
platelet and leukocyte adhesion. NO also stimulates arteriogenesis (reviewed [24]) and
mitochondrial biogenesis [25] and positively modulates mitochondrial function [26].
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Additionally, insulin prevents tumor necrosis factor (TNF) α-induced apoptosis of endothelial
cells by inhibiting caspase-9 activity [27] and increases the expression of antioxidant enzymes,
including heme oxygenase-1 (HO-1) through the PI-3K/Akt pathway [28].
Activation of the insulin receptor creates a ‘burst’ of intracellular reactive oxygen species
(ROS), including hydrogen peroxide (H2O2). At normal physiological concentrations, H2O2
transiently inactivates negative regulators of insulin signaling, including protein tyrosine
phosphatase 1B (PTP1B), protein phosphatase 2A (PP2A), and phosphatase and tensin
homolog (PTEN). Thus, when the insulin receptor is activated, the resulting burst of H2O2, in
effect, removes inhibition of signal transduction through the insulin signaling cascade.
In summary, insulin stimulates two pathways in the endothelium. One leads to the produc‐
tion of the vasodilator NO through PI3K and Akt, whereas the other mediates production of
the vasoconstrictor ET-1 through MAPK (Figure 1).
Figure 1. Insulin, vasodilation and vasoconstriction, pathways in the endothelium. IRS-1 and 2, insulin receptor sub‐
strate-1 and -2; PI-3K, phosphoinosiditde 3-kinase; Akt or PKB, protein kinase B; eNOS, endothelial nitric oxide syn‐
thase; Shc, Src homology containing; MAPK, mitogen-activated protein kinase pathway; PAI-1, plasminogen activator
inhibitor type-1; ICAM-1, intracellular adhesion molecule; VCAM-1, vascular cell adhesion molecule; ET-1, endothe‐
lin-1.
2.2. Vascular effects
Insulin-stimulated production of NO from endothelium leads to capillary recruitment,
vasodilation, increased blood flow to target tissues (e.g., skeletal muscle), and subsequent
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augmentation of glucose disposal. Removal of the endothelium or inhibition of NOS ablates
insulin-stimulated vasodilation in vitro [29-34], and insulin-mediated blood flow is abolished
by co-administration of the NOS inhibitor L-NG-monomethyl-L-arginine (L-NMMA) in vivo
[35, 36], establishing the critical role of NO in insulin-stimulated vasodilation.
Increases in circulating insulin that accompany ingestion of a mixed meal or a glucose
challenge increase limb blood flow and decrease vascular resistance [9, 37]. Insulin-stimulated
production of NO from the vascular endothelium leads to increases in skeletal muscle blood
flow in vivo, and these increases have been proposed to occur in two phases [8]. The first occurs
within five minutes of insulin stimulation and involves the dilation of terminal arterioles that
increase the number of perfused capillaries (i.e., capillary recruitment) without concomitant
changes in total limb blood flow [38]. Subsequently, there is a relaxation of larger resistance
vessels, which increases overall limb blood flow; this effect can be observed within 30 minutes
of insulin stimulation, while peak flow is reached after two hours [39].
As previously described, PI-3K-dependent insulin-signaling pathways regulate vasodilator
actions of insulin, while the MAPK-dependent insulin-signaling pathways promote vasocon‐
strictor actions of insulin. Nevertheless, in the absence of disease, the opposing cardiovascular
actions of insulin exist in a balance that support cardiovascular and metabolic homeostasis.
Baron [40] was the first to theorize that the ability of insulin to increase limb/muscle blood flow
might be a critical component of insulin-stimulated glucose uptake. Indeed, a number of
studies have demonstrated a strong correlation between limb blood flow and glucose uptake
across a broad range of insulin infusion rates [1, 2, 12-14, 41, 42]. Intravenous infusion of insulin
is reported to increase total limb blood flow in the majority [2, 5, 40, 43-46] but not all [47-50]
human studies. There are a number of theories to explain why an insulin-stimulated increase
in blood flow is not always observed. Discrepancies among studies could be the result of
differences in subject selection as well as differences in physical fitness, muscularity, endo‐
thelial function, and capillary density of study subjects. Technical limitations or differences in
sensitivity of various experimental approaches for estimating limb blood flow (e.g., plethys‐
mography, thermodilution, dye dilution, Doppler ultrasound) may also contribute to contra‐
dictory reports. It has been suggested that while an increase in total blood flow is not always
observed, insulin can re-distribute blood flow by influencing which vessels are perfused
without affecting total blood flow [51, 52].
Insulin modulates microvascular perfusion through the relaxation of terminal arteries and
through capillary recruitment [38, 40, 44, 46, 53-55]. Strong correlations between measures of
insulin-mediated capillary recruitment and skeletal muscle glucose uptake [14, 54] have been
viewed by some as evidence of insulin regulating ‘nutritive’ blood flow[5, 52-54]. In other
words, insulin may promote the dilation of specific terminal arterioles to increase perfusion
of capillary beds that experience little or no perfusion under basal conditions [52]. Support for
this notion comes from a number of studies demonstrating that increases in capillary recruit‐
ment and microvascular blood flow precede increases in glucose uptake in response to insulin,
whereas changes in bulk limb blood flow are typically observed after the onset of changes in
glucose disposal [44]. Together, these data suggest that changes in bulk flow may be secondary
to changes in capillary recruitment.
Insulin Resistance and Endothelial Dysfunction: Macro and Microangiopathy
http://dx.doi.org/10.5772/56475
7
In addition to stimulating vasodilation, insulin promotes opposing mechanisms which lead to
vasoconstriction, including activation of the sympathetic nervous system and secretion of the
vasoconstrictor ET-1 from the endothelium [56, 57]. Increases in sympathetic nerve activity
and circulating catecholamines are observed following insulin infusion or meal ingestion
[58-60]. The sympatho-excitatory effects of insulin are thought to function primarily to
maintain blood pressure by offsetting peripheral vasodilation [58]. In support of this theory,
insulin decreases blood pressure in persons with autonomic failure [61], and, in patients who
have undergone regional sympathectomy, increases in blood flow in the denervated limb
precede changes in blood flow in the innervated limb [62]. Although there is evidence of
cholinergic involvement in hemodynamic responses to insulin in rats [63], neither cholinergic
nor β-adrenergic systems appear to be involved in humans [64].
3. Insulin resistance and endothelial dysfunction
3.1. Signaling pathways
3.1.1. Changes in insulin signaling in the endothelium in insulin resistance
Lipotoxicity, glucotoxicity, and inflammation disrupt insulin signaling in the endothelium and
lead to reduced insulin-stimulated blood flow in obesity and type 2 diabetes.
3.1.2. Reactive oxygen species
In type 2 diabetes, glucotoxicity and lipotoxicity, stimulate the production of ROS. Elevations
in ROS contribute to the development and progression of vascular complications associated
with type 2 diabetes by directly interfering with insulin signaling and limiting NO bioavaila‐
bility.
Hyperglycemia activates the polyol pathway, converting excess glucose to sorbitol and finally
fructose [65]. When fructose reacts with proteins, lipids, and nucleic acids, advanced glycation
end products (AGE) are formed, which, in turn, stimulate ROS production [66]. Hyperglyce‐
mia further contributes to ROS by inducing peroxidation of circulating glucose and lipopro‐
teins and interfering with auto-oxidation processes [67]. Neurohormonal over-activation and
inflammation also contribute to ROS (superoxide) formation via stimulation of NADPH
oxidase activity and expression [68]. ROS generation is further compounded by reductions in
superoxide dismutase, catalase, and glutathione peroxidase, which impair antioxidant
capacity in type 2 diabetes [69].
When generated in excess, ROS impairs insulin signaling by impairing insulin-stimulated
activation of Akt and eNOS [70, 71] and limiting NO bioavailability [72]. Typically, the
production of NO occurs in a sequence of tightly coupled reactions involving eNOS, tetrahy‐
drobiopterin (BH4), and several other co-factors [73]. ROS limits BH4 availability, resulting in
eNOS uncoupling and superoxide production [73]. Additionally, ROS may interact directly
with NO to form the powerful oxidant peroxynitrite (ONOO-), which may contribute to further
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uncoupling of eNOS. In other words, excess oxidative stress diverts NO to inactivate free
radicals, thereby limiting the amount of NO available for vasoregulatory processes. Finally,
eNOS expression is reduced in type 2 diabetes, putatively as a result of reduced or altered
shear stress patterns.
3.1.3. Alternative mechanisms by which lipotoxicity and glucotoxicity interfere with insulin signaling
in the endothelium
Lipotoxicity (dyslipidemia) contributes to endothelial insulin resistance by impairing the PI3K/
Akt/eNOS branch of the insulin signaling pathway while augmenting the MAPK/ET-1 branch
[6]. Elevated free fatty acids (FFAs) and lipid metabolites (diacylglycerols, ceramides, acyl
coenzyme As) activate protein kinase C (PKC), IkB kinase β (IKKB), and nuclear factor-ĸB (NF-
ĸB), which serine phosphorylate IRS-1 [23, 74, 75]. Unlike tyrosine phosphorylation, which
activates IRS-1, serine phosphorylation deactivates IRS-1 and effectively blunts insulin-
stimulated production of NO.
Glucotoxicity activates the hexosamine biosynthetic pathway, promoting the production of
O-linked β-N-acetylglucosamine (O-GlcNAc). Insulin signaling is impaired when O-linked
glycosylation obstructs key phosphorylation sites on IRS-1 and eNOS [70, 76]. AGEs generated
as a result of hyperglycemia activate PKC, which inhibits activation of PI-3K/Akt via serine
phosphorylation of IRS-1/2 [77], as well as NF-ĸB, which increases the expression of ET-1 [78].
AGEs also accelerate the degradation of eNOS mRNA [79].
3.1.4. Cytokines, hormones, and other proteins
Elevated cytokines are associated with insulin resistance and contribute to endothelial
dysfunction. Increases in cytokines, including TNF-α, C-reactive protein (CRP), and interleu‐
kin-6 (IL-6), inhibit insulin-stimulated NO production by decreasing eNOS expression and by
activating serine kinases which serine phosphorylate and inactivate IRS-1/2, thereby inhibiting
the PI3K/Akt/eNOS pathway [8, 31, 80, 81]. Moreover, TNF-α and CRP enhance ET-1 produc‐
tion [82, 83].
Obesity and type 2 diabetes are associated with elevations in leptin and resistin, which
contribute to increases in TNF-α, IL-6, ROS, and ET-1 [84-87]. Leptin also enhances serine
phosphorylation of IRS-1, thereby impairing insulin signaling through the PI-3K/Akt pathway
[88]. Resistin, on the other hand, reduces eNOS expression [89]. Conversely, although adipo‐
nectin and ghrelin stimulate NO production through PI-3K/Akt signaling pathways and
enhance NO bioavailability [90-92], both are reduced in individuals who are obese or have
type 2 diabetes.
3.1.5. Proatherogenic effects of insulin
Insulin also stimulates the expression of pro-atherogenic molecules in the endothelium
through MAPK-dependent pathways [93], including, plasminogen activator inhibitor type-1
(PAI-1) [94], intracellular adhesion molecule (ICAM-1) [95], vascular cell adhesion molecule
(VCAM-1) [95], and E-selectin [95]. Inhibition of PI-3K or Akt results in increased expression
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of these pro-atherogenic molecules, indicating that the PI-3K/Akt pathway may inhibit the
expression of atherothrombic factors in addition to stimulating the production of protective
molecules, including NO [95].
3.2. Vascular effects
The vascular actions of insulin are altered in insulin resistant states owing to impairments in
the PI3K/Akt/eNOS pathway, over-activation of the MAPK/ET-1 pathway, and/or altered
bioavailability of or sensitivity to NO and/or ET-1. Furthermore, impairments in vascular
responses to insulin are proportional to the degree of metabolic insulin resistance [43, 96].
Shared causal factors such as glucotoxicity, lipotoxicity, inflammation, and oxidative stress
interact at multiple levels to create reciprocal relationships between insulin resistance and
endothelial dysfunction that may help explain the frequent clustering of metabolic and
cardiovascular disorders [8].
There is a strong association between insulin resistance and endothelial dysfunction, measured
in terms of impaired endothelium-dependent vasodilatation [97, 98]. For instance, in healthy
volunteers there is a close correlation between insulin sensitivity and basal NO production
[99]. In addition, insulin-resistant humans have impaired endothelium-dependent vasodilator
responses, measured using a variety of techniques [97, 100]. Endothelial dysfunction is also
detectable in healthy first-degree relatives of patients with type 2 diabetes, who are themselves
at increased risk of developing diabetes [101].
Furthermore, reduced efficacy of insulin to stimulate blood flow has been demonstrated in
obesity, type 2 diabetes, and polycystic ovarian syndrome [45, 102]. The relationship between
insulin resistance and endothelial dysfunction is independent of traditional cardiovascular
risk factors (including blood pressure, plasma cholesterol, and triglycerides), yet a potential
contribution of other confounding factors cannot be ruled out. Animal studies have also
described similar findings [103-105]. Winters et al. reported impaired endothelium-dependent
vasodilatation in mice with obesity and insulin resistance secondary to a naturally occurring
gene mutation [103]. Transgenic mice with perturbations of the insulin-signaling pathway
causing insulin resistance exhibit impairment of endothelium-dependent vasodilatation,
whilst the response to exogenous NO donors remains intact [105].
Insulin resistance results in a selective impairment of the vasodilating and anti-atherogenic
PI3-K/Akt pathway, whereas MAPK pathway remains unaffected [6, 106]. As a result, the
compensatory hyperinsulinaemia occurring in insulin resistant states overactivates the MAPK
pathway, favoring vasoconstriction. Insulin resistance and hyperinsulinemia transpire
concurrently, rendering the deleterious consequences on endothelial function more severe
than the sum of each alone.
Clinical studies have shown that high free fatty acid concentrations are associated with
impairment of endothelium-dependent vasodilation and increased blood pressure [4, 107],
putatively as a consequence of decreased NO availability. As previously mentioned, one of
the characteristics of insulin resistance is the presence of chronic low grade inflammation along
with increased circulating levels of cytokines and of inflammatory markers, including TNF-
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α[108, 109]. Interestingly, TNF-α concentrations are negatively associated with capillary
recruitment, perhaps explaining, at least in part, its relationship with insulin resistance [110].
ET-1 plays a pivotal role in insulin resistance and vascular dysfunction [111], as shown by
experiments carried out both in vitro and in vivo. In vitro, sustained exposure of insulin-
responsive cells to ET-1 impairs insulin sensitivity [112, 113]. Similarly, ET-1 causes insulin
resistance in vivo, which may be prevented by administration of drugs which interfere with
the ET-1 receptor type A [114].
The loss of skeletal muscle capillary density is observed in insulin resistance and type 2
diabetes, and insulin action is positively correlated with capillary density [115]. Furthermore,
vasodilation in skeletal muscle in response to insulin infusion is reduced in obese subjects in
comparison with lean controls [43]. Insulin-mediated capillary recruitment is blunted in cases
of insulin resistance and obesity and is tightly linked to impairments in glucose uptake [52,
116]. Under conditions of insulin resistance, the balance of insulin action shifts toward
vasoconstriction. This further exacerbates insulin resistance by limiting the delivery of insulin
and nutrients to myocytes by decreasing nutritive flow and available capillary surface area.
4. Vascular insulin resistance and the role of exercise
Physical activity may be beneficial in slowing the initiation and progression of insulin
resistance and cardiovascular disease through favorable effects on body weight, insulin
sensitivity, glycemic control, blood pressure, lipid profiles, fibrinolysis, inflammatory defense
systems, and endothelial function [117]. For instance, exercise exerts many of the same effects
in the muscle vasculature as insulin [118]. Exercise efficiently increases muscle capillary
recruitment, as well as total muscle blood flow [119]. Furthermore, exercise effects are thought
to be mediated by intermittent shear stress (tangential force of blood flowing on the endothelial
surface), an established physiological stimulus for NO [120]. Extensive comprehensive reviews
regarding the global beneficial effects and/or recommendations of exercise/physical activity
in patients with insulin resistance have been previously published elsewhere [117, 121-123].
The following section is intended to present the available evidence of the beneficial effects of
exercise/physical activity on endothelial function.
4.1. Acute effects of exercise
Studies examining the acute effects of aerobic exercise training on endothelial function in
insulin resistance subjects with few or no other major comorbidities are limited. One study
examined blood ET-1 (a powerful endogenous vasoconstrictor) levels and leg blood flow
during insulin infusions in healthy older subjects (non-diabetic and physically active, ~70 years
of age) that were assigned into exercise training and control groups. The exercise training
group treadmill exercised for 45-min at 70% of maximum heart rate. Only in the exercise
training group did leg blood flow at baseline tend to increase while ET-1 blood plasma levels
declined [124].
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Other studies demonstrating declines in insulin sensitivity in response to acute physical
inactivity in healthy populations [125-127] are corroborated by evidence that reducing
sedentary time in order to improve metabolic health is equally if not more important than the
benefits associated with a physically active lifestyle [128, 129]. Importantly, unfavorable
changes in insulin sensitivity with the bed rest [125] were associated with decreases in forearm
and calf flow-mediated dilation (FMD), an index of vascular endothelial function. Basal arterial
tone also increased with bed rest as evidenced by decreased brachial artery diameter and
increased systolic blood pressure.
4.2. Chronic effects of exercise training
Although studies examining the chronic effects of aerobic exercise training on endothelial
function in persons with insulin resistance or type 2 diabetes range widely in their experi‐
mental design, the results of these studies indicate that exercise training improves endothelial
function. For instance, in obese insulin resistant males and females, exercising three times per
week (30-min each time using an unspecified modality) at 60- 80% of maximal heart rate under
supervision and at home for at least 150-min/week for 6 months improved brachial FMD [130].
Conversely, microvascular reactivity did not improve following the exercise program in the
same subjects. Furthermore, in hemodialysis patients, a 3-month aerobic exercise training
program improved arterial stiffness (assessed using artery pressure waveform analysis) [131].
Exercise training also improves/maintains endothelial function in the obese Zucker rats (OZ),
a model of insulin resistance and obesity, relative to non-exercising OZ. A treadmill exercise
program (24 m/min, 30-min/day, 5 days/wk for 4-6wks) was shown to improve functional
hyperemia and endothelial-dependent vasodilation in the spinotrapezius microvasculature
when measured using intravital microscopy [132]. The same exercise program improved
microvascular endothelial function in OZ due to decreased thromboxane receptor-mediated
vasoconstriction [133], and not due to increased blood pressure [132]. It should be noted that
these OZ studies were conducted at single time-points while the rats were developing and/or
had already developed insulin resistance. See the “OLETF” studies described below for a
summary of the effects of exercise on endothelial function during insulin resistance time-
course studies.
Similar to the effects of acute physical inactivity, chronic physical inactivity (~6 years) led to
the development of insulin resistance and reduced FMD in lean adult male rhesus monkeys
[127]. Furthermore, insulin-mediated changes in capillary blood volume were inversely
correlated with the degree of insulin resistance and directly with physical activity levels.
Studies using the Otsuka Long-Evans Tokushima Fatty (OLETF) rat model of insulin resistance
and obesity have revealed that chronic aerobic physical activity alone (i.e. free access to
running wheels from 12-40 weeks of age) maintains/improves endothelial function in conduit
[134] and resistance arteries [34, 135-137]. These studies established that the maintained/
improved endothelial function in the OLETFs was mediated by improvements in NO signaling
and/or attenuated ET-1 sensitivity and/or production. Additionally, insulin resistance mani‐
fested prior to significant progressive declines (20-35%) in endothelial function [134]. Other
OLETF studies demonstrating the positive effect of exercise training (i.e. a training program
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on a treadmill) as an interventional measure for endothelial function were conducted at single
time-points while the rats were developing and/or had developed insulin resistance [138, 139].
It deserves mention that the experimental design of the OZ [132, 133] and several OLETF [34,
134-137] studies that were described above were such that the chronic aerobic exercise training/
physical activity served as a preventative measure for endothelial dysfunction associated with
insulin resistance. Additionally, all human (for both acute and chronic studies) and some of
the OLETF studies [138, 139] discussed above the exercise training also served as an interven‐
tional measure for endothelial dysfunction associated with insulin resistance.
Although there is evidence that resistance training improves insulin-stimulated glucose
uptake, there have been few studies specifically examining the effects of resistance training on
insulin-mediated blood flow. Juel et al. [140] compared the effects of six weeks of progressive
single-leg strength training (3 days/wk, 3 sets of 10 repetitions at 70-80% of one repetition
maximum; leg press, knee extension, and hamstring curl) on leg flow determined by thermo‐
dilution during a two-stage hyperinsulinemic-euglycemic clamp in the trained and untrained
legs of ten patients with type 2 diabetes and seven male controls. Prior to the intervention,
insulin-stimulated leg blood flow was greater in controls. Following the intervention, basal
blood flow was similar between the trained and untrained legs in both groups, and leg blood
flow was higher in the trained leg during the second stage of insulin infusion in healthy
controls and during both stages in patients with type 2 diabetes. These findings seem to suggest
that resistance training may enhance insulin-mediated blood flow in healthy individuals as
well as those with type 2 diabetes. However, it is unclear whether changes in capillarity may
contribute to this response.
Chronic exercise training produces increases in the expression and activity of proteins involved
in insulin signaling and glucose uptake as well as increases in mitochondrial biogenesis and
fatty acid oxidation [141, 142]. Chronic exercise training also increases eNOS expression in
vessels experiencing increases in blood flow during exercise [143] and up-regulates antioxidant
enzymes including, superoxide dismutase and glutathione peroxidase [144]. Finally, chronic
exercise also reverses factors known to stimulate ROS formation, including, inflammation,
glucotoxicity, and lipotoxicity [144]. Together, these adaptations likely contribute to improve‐
ments in endothelial function associated with exercise training.
5. Final conclusions
In summary, insulin stimulates two pathways in the endothelium. One pathway leads to the
production of the vasodilator NO through PI3K and Akt, while the other mediates production
of the vasoconstrictor ET-1 through MAPK [6, 31, 145]. Insulin-mediated glucose disposal is
largely dependent upon the vasodilatory effects of insulin, which enhance blood flow and,
thus, delivery of glucose and insulin to target tissues. Typically, insulin-stimulated vasodila‐
tion is responsible for up to 40% of insulin-stimulated glucose disposal following a meal [8].
The glucotoxicity, lipotoxicity, and inflammation associated with insulin resistance work in
concert to alter insulin signaling, leading to an imbalance in the production of vasodilator and
vasoconstrictor substances in response to insulin. Resulting impairments in the PI3K/Akt/
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eNOS pathway concomitant with enhanced stimulation of the MAPK/ET-1 pathway precipi‐
tate hypertension, reduced blood flow, and impaired delivery of glucose and insulin to target
tissues [7, 8, 52, 146]. Similar perturbations are observed in skeletal muscle insulin signaling
in obesity and type 2 diabetes [8, 52], indicating that the metabolic and vascular insulin
resistance associated with obesity and type 2 diabetes may develop in tandem.
Alterations in vascular NO bioavailability and/or attenuated ET-1 or attenuated thromboxane
sensitivity/production appear to contribute to endothelial dysfunction associated with insulin
resistance. These studies also collectively suggest that endothelial dysfunction can be im‐
proved/maintained with acute or chronic aerobic exercise training/physical activity when used
either thru interventional or preventative measures. The beneficial effect of exercise on
vascular insulin action was consistent across studies of conduit artery blood flow in vivo and
microvascular reactivity to insulin in vitro, in both humans and rodents, and in response to
both short-term and chronic exercise training. Clearly, even in cases of prolonged disease
progression, exercise training might be able to remedy some of the effects of insulin resistance
on the vasculature.
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